Abbott Laboratories

ABT.MX·Mexico·Healthcare
Compare
2,154.68+94.68 (+4.60%)today
At close: Nov 4, 2:56 PM CST · May be delayed up to 20 min · MXN

Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2,060.00
Open2,130.00
Day range2,130.002,158.00
52-week range1,413.002,388.00
Off day high−0.15%
Off 52-week high−9.77%
Volume213
Avg. volume (3M)363
Market cap3.73T
EPS (TTM)47.48
Forward P/E—
P/E ratio (TTM)45.38
Dividend yield2.20% (47.44)
Beta (5Y)0.54
Shares outstanding1.73B
Short interest—
Earnings dateOct 21, 2026
Analyst target—
Profit margin9.75%

Against its peers

Compare in full ›
ABT.MX ABBOTINDIA.NS LLY JNJ BMY INDSWFTLAB.NS
Market cap 3.73T 565.34B 1.26T 665.19B 131.21B 31.52B
P/E (TTM) 45.4 35.0 46.0 41.9 14.2 37.0
Forward P/E — 29.4 28.3 23.8 9.6 —
Price/book 3.9 11.8 31.4 8.2 5.6 2.1
Dividend yield 2.20% 1.94% 0.49% 1.94% 3.93% —
1-year change −6.86% −7.93% +51.26% +47.79% +37.66% +240.08%
Today +4.60% −1.90% +0.61% +3.81% +4.02% −3.72%

The closest companies by business and industry (Medical Devices). Prices may be delayed up to 20 min.

Latest news

All ABT.MX news ›
eDairyNews English··4 outletsPositive

Abbott To Spin Off $8.5B Nutrition Business Into Standalone Public Company - EDairy News English

Abbott plans to spin off its $8.5B nutrition business into an independent public company by late 2027, housing Similac, Ensure, and PediaSure. Corporate separation by end of 2027 will create an independent nutrition powerhouse housing…

More from 3 other outlets
Medical Product Outsourcing·Positive

Abbott to Split Off Nutrition Biz, Q3 Sales Rise 14.5%

Medical Product Outsourcing offers a centralized destination where users can watch expert-led sessions anytime, anywhere The planned spinoff comes as Abbott reports $13 billion in third-quarter sales and narrows its 2026 earnings outlook.…

The Globe and Mail·Negative

Barclays Keeps Their Buy Rating on Abbott Laboratories (ABT)

In a report released today, Christopher Pasquale from Barclays maintained a Buy rating on Abbott Laboratories, with a price target of $120.00. According to TipRanks, Pasquale is a 4-star analyst with an average return of 9.7% and a 59.56%…

From the 4Search news index, newest first.

In the news

133mentions in 30 days
68with it in the headline
Mixedsentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance